Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 1, 2003, Pages 9-16

  Luyendyk, James P ^a   Maddox, Jane F ^a   Cosma, Gregory N ^b,c   Ganey, Patricia E ^a   Cockerell, Gary L ^b   Roth, Robert A ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; FAMOTIDINE; GAMMA GLUTAMYLTRANSFERASE; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; INFLAMMATION; LEUKOCYTE ACTIVATION; LIVER CELL; LIVER INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; XENOBIOTIC METABOLISM;

ANIMALS; ANTI-ULCER AGENTS; FAMOTIDINE; HEPATITIS, TOXIC; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; RANITIDINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0141563559     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.054288     Document Type: Article

References (30)

1. Ament PW, Roth JD, and Fox CJ (1994) Famotidine-induced mixed hepatocellular jaundice. Ann Pharmacother 28:40-42.
2. Barr GD and Piper DW (1981) Possible ranitidine hepatitis. Med J Aust 2:421.
3. Barton CC, Barton EX, Ganey PE, Kunkel SL, and Roth RA (2001) Bacterial lipopolysaccharide enhances aflatoxin B1 hepatotoxicity in rats by a mechanism that depends on tumor necrosis factor alpha. Hepatology 33:66-73.
4. Barton CC, Ganey PE, and Roth RA (2000a) Lipopolysaccharide augments aflatoxin B(1)-induced liver injury through neutrophil-dependent and -independent mechanisms. Toxicol Sci 58:208-215.
5. Barton CC, Hill DA, Yee SB, Barton EX, Ganey PE, and Roth RA (2000b) Bacterial lipopolysaccharide exposure augments aflatoxin B(1)-induced liver injury. Toxicol Sci 55:444-452.
6. Buchweitz JP, Ganey PE, Bursian SJ, and Roth RA (2002) Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 300:460-467.
7. Devuyst O, Lefebvre C, Geubel A, and Coche E (1993) Acute cholestatic hepatitis with rash and hypereosinophilia associated with ranitidine treatment. Acta Clin Belg 48:109-114.
8. Ganey PE, Bailie MB, VanCise S, Colligan ME, Madhukar BV, Robinson JP, and Roth RA (1994) Activated neutrophils from rat injured isolated hepatocytes. Lab Investig 70:53-60.
9. Ganey PE and Roth RA (2001) Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicology 169:195-208.
10. Graham DY, Opekun AR, Smith JL, and Schwartz JT (1985) Ranitidine and hepatotoxicity. Ann Intern Med 102:416.
11. Halparin LS (1984) Adverse effects of ranitidine therapy. Can Med Assoc J 130:668-669.
12. Hashimoto F, Davis RL, and Egli D (1994) Hepatitis following treatments with famotidine and then cimetidine. Ann Pharmacother 28:37-39.
13. Hewett JA, Schultze AE, Van Cise S, and Roth RA (1992) Neutrophil depletion protects against liver injury from bacterial endotoxin. Lab Investig 66:347-361.
14. Hiesse C, Cantarovich M, Santelli C, Francais P, Charpentier B, Fries D, and Buffet C (1985) Ranitidine hepatotoxicity in a renal transplant patient. Lancet 1:1280.
15. Ho JS, Buchweitz JP, Roth RA, and Ganey PE (1996) Identification of factors from rat neutrophils responsible for cytotoxicity to isolated hepatocytes. J Leukoc Biol 59:716-724.
16. Jimenez-Saenz M, Arguelles-Arias F, Herrerias-Gutierrez JM, and Duran-Quintana JA (2000) Acute cholestatic hepatitis in a child treated with famotidine. Am J Gastroenterol 95:3665-3666.
17. Lauritsen K, Havelund T, and Rask-Madsen J (1984) Ranitidine and hepatotoxicity. Lancet 2:1471.
18. Lin JH (1991) Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists: relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 20:218-236.
19. Lind RC, Gandolfi AJ, Sipes IG, and Brown BR Jr (1984) The involvement of endotoxin in halothane-associated liver injury. Anesthesiology 61:544-550.
20. Luyendyk JP, Shores KC, Ganey PE, and Roth RA (2002) Bacterial lipopolysaccharide exposure alters aflatoxin B1 hepatotoxicity: benchmark analysis for markers of liver injury. Toxicol Sci 68:220-225.
21. Okajima K, Harada N, and Uchiba M (2002) Ranitidine reduces ischemia/reperfusion-induced liver injury in rats by inhibiting neutrophil activation. J Pharmacol Exp Ther 301:1157-1165.
22. Ramrakhiani S, Brunt EM, and Bacon BR (1998) Possible cholestatic injury from ranitidine with a review of the literature. Am J Gastroenterol 93:822-826.
23. Ribeiro JM, Lucas M, Baptista A, and Victorino R-MM (2000) Fatal hepatitis associated with ranitidine. Am J Gastroenterol 95:559-560.
24. Roth RA, Harkema JR, Pestka JP, and Ganey PE (1997) Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol Appl Pharmacol 147:300-311.
25. Scarpignato C, Tramacere R, and Zappia L (1987) Antisecretory and antiulcer effect of H2-receptor antagonist famotidine in the rat: comparison with ranitidine. Br J Pharmacol 92:153-159.
26. Souza Lima MA (1984) Hepatitis associated with ranitidine. Ann Intern Med 101:207-208.
27. Vial T, Goubier C, Bergeret A, Cabrera F, Evreux J-C, and Descotes J (1991) Side effects of ranitidine. Drug Saf 6:94-117.
28. Yee SB, Hanumegowda UM, Hotchkiss JA, Ganey PE, and Roth RA (2003) Role of neutrophils in the synergistic liver injury from monocrotaline and bacterial lipopolysaccharide exposure. Toxicol Sci 72:43-56.
29. Yee SB, Kinser S, Hill DA, Barton CC, Hotchkiss JA, Harkema JR, Ganey PE, and Roth RA (2000) Synergistic hepatotoxicity from coexposure to bacterial endotoxin and the pyrrolizidine alkaloid monocrotaline. Toxicol Appl Pharmacol 166:173-185.
30. Zimmerman HJ, Jacob L, Bassan H, Gillespie J, Lukacs L, and Abernathy CO (1986) Effects of H2-blocking agents on hepatocytes in vitro: correlation with potential for causing hepatic disease in patients. Proc Soc Exp Biol Med 182:511-514.